MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-101802-PIP01-25)

MHRA-101802-PIP01-25-M01

Scope of the Application

Active Substance(s)

Recombinant human tissue nonspecific alkaline phosphatase (TNSALP) fragment crystallizable (Fc) deca aspartate fusion protein; Efzimfotase alfa

Condition(s)

Treatment of hypophosphatasia

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

SUBCUTANEOUS USE

Name / Corporate name of the PIP applicant

Alexion Europe SAS

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Alexion Europe SAS submitted to the licensing authority on 04/12/2025 14:44 GMT an application for a Modification

The procedure started on 12/12/2025 09:24 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101802-PIP01-25-M01

Of 01/04/2026 17:45 BST

On the adopted decision for Recombinant human tissue nonspecific alkaline phosphatase (TNSALP) fragment crystallizable (Fc) deca aspartate fusion protein; Efzimfotase alfa (MHRA-101802-PIP01-25-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for Recombinant human tissue nonspecific alkaline phosphatase (TNSALP) fragment crystallizable (Fc) deca aspartate fusion protein; Efzimfotase alfa , Solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Alexion Europe SAS, 103-105 rue Anatole, Levallois-Perret, FRANCE, 92300

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of hypophosphatasia

2.2 Indication(s) targeted by the PIP:

Treatment of hypophosphatasia

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	1	Study 1 Dose range-finding toxicity study in juvenile rats.
Clinical Studies	4	Study 2 (ALXN1850-HPP-301) Double-blind, randomised, placebo-controlled trial to evaluate efficacy and safety of ALXN1850 in adolescents from 12 years to less than 18 years of age (and adults) with hypophosphatasia naïve to treatment with asfotase alfa. Study 3 (ALXN1850-HPP-305) Double-blind, randomised, placebo-controlled trial to evaluate efficacy and safety of ALXN1850 in children from 2 years to less than 12 years of age with hypophosphatasia naïve to treatment with asfotase alfa. Study 4 (ALXN1850-HPP-303) Open-label, randomised, active-controlled (asfotase alfa) trial to evaluate safety and efficacy of ALXN1850 in children from 2 years to less than 12 years of age with hypophosphatasia previously treated with asfotase alfa. Study 5 Open-label, single-arm trial to evaluate pharmacokinetics, pharmacodynamics and safety of ALXN1850 in children from birth to less than 2 years of age with hypophosphatasia.
Extrapolation, Modeling & Simulation Studies	2	Study 6 ALXN1850 modelling and simulation study to support

		dose selection on patients below 2 years of age with hypophosphatasia. Extrapolation Plan Studies 2, 3, 4 and 5 are part of an extrapolation plan covering the paediatric population from birth to less than 18 years of age.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	30/06/2033
Deferral of one or more studies contained in the paediatric investigation plan:	Yes